0	10	Triggering	triggering	NN
11	13	of	of	IN
14	20	HLA-DR	HLA-DR	NNP
21	29	antigens	antigen	NNS
30	44	differentially	differentially	RB
45	54	modulates	modulate	VBZ
55	60	tumor	tumor	NN
61	69	necrosis	necrosis	NN
70	76	factor	factor	NN
77	82	alpha	alpha	NN
83	90	release	release	NN
91	93	by	by	IN
94	95	B	B	NNP
96	101	cells	cell	NNS
102	104	at	at	IN
105	113	distinct	distinct	JJ
114	119	stage	stage	NN
120	122	of	of	IN
123	133	maturation	maturation	NN
133	134	.	.	.

136	146	Triggering	triggering	NN
147	149	of	of	IN
150	153	HLA	HLA	NNP
154	159	class	class	NN
160	162	II	ii	CD
163	171	antigens	antigen	NNS
172	174	by	by	IN
175	178	the	the	DT
179	190	anti-HLA-DR	anti-hla-dr	JJ
191	201	monoclonal	monoclonal	JJ
202	210	antibody	antibody	NN
211	212	(	(	(
212	215	mAb	mab	NN
215	216	)	)	)
217	221	L243	l243	NN
222	235	significantly	significantly	RB
236	237	(	(	(
237	238	P	p	NN
239	240	<	<	SYM
241	245	0.05	0.05	CD
245	246	)	)	)
247	250	and	and	CC
251	265	differentially	differentially	RB
266	274	enhanced	enhance	VBD
275	278	the	the	DT
279	286	release	release	NN
287	289	of	of	IN
290	295	tumor	tumor	NN
296	304	necrosis	necrosis	NN
305	311	factor	factor	NN
312	317	alpha	alpha	NN
318	319	(	(	(
319	328	TNF-alpha	TNF-alpha	NNP
328	329	)	)	)
330	332	by	by	IN
333	336	the	the	DT
337	348	non-Hodgkin	non-hodgkin	NN
348	350	’s	's	POS
351	359	lymphoma	lymphoma	NN
360	365	cells	cell	NNS
366	370	Ri-I	Ri-I	NNP
370	371	,	,	,
372	376	Ci-I	Ci-I	NNP
376	377	,	,	,
378	381	and	and	CC
382	386	Sc-I	Sc-I	NNP
386	387	,	,	,
388	393	which	which	WDT
394	397	are	be	VBP
398	400	at	at	IN
401	402	a	a	DT
403	411	distinct	distinct	JJ
412	417	stage	stage	NN
418	420	of	of	IN
421	427	B-cell	b-cell	NN
428	443	differentiation	differentiation	NN
443	444	,	,	,
445	448	and	and	CC
449	451	by	by	IN
452	455	the	the	DT
456	460	more	more	RBR
461	467	mature	mature	JJ
468	475	Burkitt	Burkitt	NNP
476	484	lymphoma	lymphoma	NN
485	489	cell	cell	NN
490	494	Raji	Raji	NNP
494	495	;	;	:
496	498	in	in	IN
499	507	contrast	contrast	NN
507	508	,	,	,
509	511	it	it	PRP
512	515	did	do	VBD
516	519	not	not	RB
520	526	induce	induce	VB
527	536	TNF-alpha	TNF-alpha	NNP
537	544	release	release	NN
545	547	by	by	IN
548	551	the	the	DT
552	557	pre-B	pre-b	JJ
558	566	leukemia	leukemia	NN
567	572	cells	cell	NNS
573	579	Nalm-6	Nalm-6	NNP
580	583	and	and	CC
584	589	BV173	BV173	NNP
589	590	.	.	.

591	600	TNF-alpha	TNF-alpha	NNP
601	608	release	release	NN
609	615	peaked	peak	VBD
616	618	at	at	IN
619	621	24	24	CD
622	623	h	h	NN
624	627	and	and	CC
628	637	decreased	decrease	VBD
638	648	thereafter	thereafter	RB
648	649	,	,	,
650	653	and	and	CC
654	656	it	it	PRP
657	660	was	be	VBD
661	665	dose	dose	NN
666	675	dependent	dependent	JJ
676	679	and	and	CC
680	688	preceded	precede	VBN
689	691	by	by	IN
692	694	an	an	DT
695	703	increase	increase	NN
704	706	of	of	IN
707	716	TNF-alpha	TNF-alpha	NNP
717	721	mRNA	mRNA	NNP
722	732	detectable	detectable	JJ
733	738	after	after	IN
739	740	3	3	CD
741	742	h	h	NN
743	745	of	of	IN
746	757	stimulation	stimulation	NN
758	762	with	with	IN
763	766	mAb	mab	NN
767	771	L243	l243	NN
771	772	.	.	.

773	781	Secreted	secrete	VBN
782	791	TNF-alpha	TNF-alpha	NNP
792	800	mediated	mediate	VBD
801	804	the	the	DT
805	816	enhancement	enhancement	NN
817	819	of	of	IN
820	827	nuclear	nuclear	JJ
828	834	factor	factor	NN
835	840	kappa	kappa	NN
841	842	B	B	NNP
843	844	(	(	(
844	852	NF-kappa	NF-kappa	NNP
853	854	B	B	NNP
854	855	)	)	)
856	859	and	and	CC
860	869	activator	activator	NN
870	879	protein-1	protein-1	NN
880	881	(	(	(
881	885	AP-1	ap-1	NN
885	886	)	)	)
887	894	binding	binding	NN
895	903	activity	activity	NN
903	904	;	;	:
905	907	in	in	IN
908	912	fact	fact	NN
912	913	,	,	,
914	917	the	the	DT
918	928	triggering	triggering	NN
929	931	of	of	IN
932	938	HLA-DR	HLA-DR	NNP
939	947	antigens	antigen	NNS
948	950	in	in	IN
951	954	the	the	DT
955	963	presence	presence	NN
964	966	of	of	IN
967	976	antihuman	antihuman	JJ
977	999	TNF-alpha-neutralizing	tnf-alpha-neutralizing	JJ
1000	1010	antibodies	antibody	NNS
1011	1014	did	do	VBD
1015	1018	not	not	RB
1019	1029	upregulate	upregulate	VB
1030	1038	NF-kappa	NF-kappa	NNP
1039	1040	B	B	NNP
1041	1044	and	and	CC
1045	1049	AP-1	AP-1	NNP
1049	1050	.	.	.

1051	1053	In	in	IN
1054	1062	contrast	contrast	NN
1062	1063	,	,	,
1064	1072	released	release	VBN
1073	1082	TNF-alpha	TNF-alpha	NNP
1083	1086	was	be	VBD
1087	1090	not	not	RB
1091	1102	responsible	responsible	JJ
1103	1106	for	for	IN
1107	1110	the	the	DT
1111	1120	homotypic	homotypic	JJ
1121	1132	aggregation	aggregation	NN
1133	1135	of	of	IN
1136	1140	Ri-I	Ri-I	NNP
1140	1141	,	,	,
1142	1146	Ci-I	Ci-I	NNP
1146	1147	,	,	,
1148	1152	Sc-I	Sc-I	NNP
1152	1153	,	,	,
1154	1157	and	and	CC
1158	1162	Raji	Raji	NNP
1163	1168	cells	cell	NNS
1169	1176	induced	induce	VBN
1177	1179	by	by	IN
1180	1183	mAb	mab	NN
1184	1188	L243	l243	NN
1188	1189	,	,	,
1190	1193	and	and	CC
1194	1196	it	it	PRP
1197	1200	did	do	VBD
1201	1204	not	not	RB
1205	1211	affect	affect	VB
1212	1215	the	the	DT
1216	1229	proliferation	proliferation	NN
1230	1232	of	of	IN
1233	1234	B	B	NNP
1235	1240	cells	cell	NNS
1241	1253	investigated	investigate	VBN
1253	1254	.	.	.

1255	1265	Altogether	altogether	RB
1265	1266	,	,	,
1267	1270	our	our	PRP$
1271	1275	data	datum	NNS
1276	1287	demonstrate	demonstrate	VBP
1288	1292	that	that	IN
1292	1293	:	:	:
1294	1295	(	(	(
1295	1296	a	a	LS
1296	1297	)	)	)
1298	1301	the	the	DT
1302	1309	ability	ability	NN
1310	1312	of	of	IN
1313	1314	B	B	NNP
1315	1320	cells	cell	NNS
1321	1323	to	to	TO
1324	1331	release	release	VB
1332	1341	TNF-alpha	TNF-alpha	NNP
1342	1347	after	after	IN
1348	1358	triggering	triggering	NN
1359	1361	of	of	IN
1362	1368	HLA-DR	HLA-DR	NNP
1369	1377	antigens	antigen	NNS
1378	1385	depends	depend	VBZ
1386	1388	on	on	IN
1389	1394	their	their	PRP$
1395	1400	stage	stage	NN
1401	1403	of	of	IN
1404	1419	differentiation	differentiation	NN
1419	1420	;	;	:
1421	1422	(	(	(
1422	1423	b	b	LS
1423	1424	)	)	)
1425	1431	levels	level	NNS
1432	1434	of	of	IN
1435	1443	released	release	VBN
1444	1453	TNF-alpha	TNF-alpha	NNP
1454	1458	seem	seem	VBP
1459	1461	to	to	TO
1462	1471	correlate	correlate	VB
1472	1476	with	with	IN
1477	1480	the	the	DT
1481	1486	stage	stage	NN
1487	1489	of	of	IN
1490	1496	B-cell	b-cell	NN
1497	1507	maturation	maturation	NN
1508	1511	but	but	CC
1512	1514	do	do	VBP
1515	1518	not	not	RB
1519	1528	correlate	correlate	VB
1529	1533	with	with	IN
1534	1537	the	the	DT
1538	1545	amounts	amount	NNS
1546	1548	of	of	IN
1549	1553	cell	cell	NN
1554	1561	surface	surface	NN
1562	1568	HLA-DR	hla-dr	NN
1569	1577	antigens	antigen	NNS
1577	1578	;	;	:
1579	1580	(	(	(
1580	1581	c	c	LS
1581	1582	)	)	)
1583	1591	secreted	secrete	VBN
1592	1601	TNF-alpha	TNF-alpha	NNP
1602	1611	regulates	regulate	VBZ
1612	1615	the	the	DT
1616	1622	levels	level	NNS
1623	1625	of	of	IN
1626	1636	expression	expression	NN
1637	1639	of	of	IN
1640	1648	NF-kappa	NF-kappa	NNP
1649	1650	B	B	NNP
1651	1654	and	and	CC
1655	1659	AP-1	ap-1	NN
1660	1662	by	by	IN
1663	1665	an	an	DT
1666	1675	autocrine	autocrine	JJ
1676	1680	loop	loop	NN
1680	1681	;	;	:
1682	1685	and	and	CC
1686	1687	(	(	(
1687	1688	d	d	LS
1688	1689	)	)	)
1690	1703	intracellular	intracellular	JJ
1704	1711	signals	signal	NNS
1712	1721	mediating	mediate	VBG
1722	1731	TNF-alpha	TNF-alpha	NNP
1732	1739	release	release	NN
1740	1742	by	by	IN
1743	1744	B	B	NNP
1745	1750	cells	cell	NNS
1751	1754	are	be	VBP
1755	1763	distinct	distinct	JJ
1764	1768	from	from	IN
1769	1774	those	those	DT
1775	1785	regulating	regulate	VBG
1786	1795	homotypic	homotypic	JJ
1796	1807	aggregation	aggregation	NN
1808	1811	and	and	CC
1812	1825	proliferation	proliferation	NN
1825	1826	.	.	.